NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective March 1, 2022, the Compensation Committee of the Board of Directors approved an equity award under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the "Inducement Plan"), as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of awards that are not made under a stockholder approved equity plan. 

In connection with entering into employment with NeuroOne, the individual, who was not previously an employee or director of NeuroOne, received an option to purchase 10,000 shares of the Company`s common stock. The option award has an exercise price of $1.95 per share, the closing price of NeuroOne`s common stock on March 1, 2022, the date of the grant. The option has a ten-year term and vests as to 25% on March 1, 2023, with the remaining shares vesting in equal monthly installments on the last day of each month over the next thirty-six (36) months, provided the new hire`s employment is continuing on each such date.